Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | -1.67% | -4.84% | +11.27% |
Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 18.89M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.97
x | P/E ratio 2025 * |
-
| Employees | 1 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.61% |
Latest transcript on Alaunos Therapeutics, Inc.
1 day | -1.67% | ||
1 week | -4.84% | ||
Current month | -34.81% | ||
1 month | -36.56% | ||
3 months | -57.50% | ||
6 months | -21.49% | ||
Current year | +11.27% |
Managers | Title | Age | Since |
---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
Director of Finance/CFO | 62 | 21-02-16 | |
Chief Tech/Sci/R&D Officer | 44 | 22-08-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 20-12-15 |
Holger Weis
CHM | Chairman | 61 | 20-12-15 |
Robert Postma
BRD | Director/Board Member | 70 | 21-02-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.18 | -1.67% | 30,372 |
24-04-23 | 1.2 | +10.09% | 46,815 |
24-04-22 | 1.09 | -2.68% | 38,305 |
24-04-19 | 1.12 | -8.94% | 49,732 |
24-04-18 | 1.23 | -0.81% | 33,088 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.27% | 19.21M | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- TCRT Stock